Cyramza

(Ramucirumab)

Phase 3Monoclonal antibody

Ramucirumab is used to treat certain types of advanced cancers, including stomach cancer, lung cancer, and colorectal cancer, by blocking a protein that helps tumors grow and spread.[1] Cyramza is currently being investigated across 22 indications[3], with its most advanced program in Phase 3.[1]

Cyramza is one of 323 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.

Indications

137

Total Trials

Active Trials

322

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Solid TumorActive, not recruiting

PembrolizumabTerminated

Gastric CarcinomaUnknown

Non-Small Cell Lung CarcinomaUnknown

Gastric AdenocarcinomaRecruiting

Gastric CancerActive, not recruiting

Stomach NeoplasmUnknown

NeoplasmsRecruiting

Advanced Esophageal AdenocarcinomaRecruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Solid TumorPhase 1

Active, not recruiting

PembrolizumabPhase 2

Terminated

Gastric CarcinomaPreclinical

Unknown

Non-Small Cell Lung CarcinomaPreclinical

Unknown

Gastric AdenocarcinomaPhase 2

Recruiting

Gastric CancerPhase 3

Active, not recruiting

Stomach NeoplasmPreclinical

Unknown

NeoplasmsPhase 2

Recruiting

Advanced Esophageal AdenocarcinomaPreclinical

Recruiting

Showing 10 of 22 indications

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

6 2

Cyramza

Eli Lilly

Phase 3

18 3

SCTB14

SSinocelltech Ltd.

Phase 3

1 4

Second-Line Systemic Therapy

SSun Yat-sen University

Phase 3

1 5

Remeron

OOrganon and Co

Preclinical

1 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—9

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 10

Treatment

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Gastric Cancer

NCT06346392

Phase 3Active, not recruiting

Metastatic NSCLC

NCT02411448

Phase 2Active, not recruiting

Biliary Tract Cancer

NCT02711553

Phase 1Active, not recruiting

Non-Small Cell Lung Cancer

NCT06542731

Phase 2Active, not recruiting

Metastatic Lung Non-Squamous Non-Small Cell Carcinoma

NCT04310007

Q2 2027

Phase 2Active, not recruiting

Metastatic NSCLC

NCT03527108

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer18 trials

An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer

Active, not recruiting· Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd·Phase 1·NCT06542731·42 enrolled

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT04151563

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Recruiting·SSWOG Cancer Research Network·Phase 2·NCT05642572·66 enrolled

Show 15 more trials

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Active, not recruiting·SSWOG Cancer Research Network·Phase 3·NCT05633602·838 enrolled

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Recruiting·SSWOG Cancer Research Network·Phase 2·NCT06031688·56 enrolled

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting·XXiuning Le·Phase 2·NCT03909334·160 enrolled

Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Completed·LLiza Villaruz, MD·Phase 2·NCT02730247·7 enrolled

A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer

Withdrawn· Eli Lilly logo

Eli Lilly·Phase 2·NCT02831491

A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT01168973·1,253 enrolled

A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01703091·197 enrolled

A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00735696·41 enrolled

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Recruiting·SSWOG Cancer Research Network·Phase 2/3·NCT06616584·378 enrolled

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Active, not recruiting·SSWOG Cancer Research Network·Phase 2/3·NCT05096663·82 enrolled

Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer

Completed·OOhio State University Comprehensive Cancer Center·Phase 2·NCT04120454·6 enrolled

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

Completed·SSWOG Cancer Research Network·Phase 2·NCT03971474·166 enrolled

A Phase II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Volrustomig Priming Regimens in Combination With Other Anticancer Agents in Participants With Solid Tumors (eVOLVE-01)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT06448754·194 enrolled

A Phase 1/2 Study of Combination Lorlatinib and Ramucirumab in Patients With Advanced ALK-rearranged Lung Cancers

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Preclinical·NCT06007937·9 enrolled

An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT07098338·278 enrolled

Gastric Cancer10 trials

Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer

Terminated· Sanofi logo

Sanofi·Phase 2·NCT05071053·35 enrolled

A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06564298·39 enrolled

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

Active, not recruiting·AALX Oncology Inc.·Phase 2/3·NCT05002127·127 enrolled

Show 7 more trials

Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT02726399·7 enrolled

Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer

Withdrawn·KKorean South West Oncology Group·Phase 2·NCT03766607

Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial

Active, not recruiting·RRoyal Marsden NHS Foundation Trust·Phase 2·NCT02678182·494 enrolled

A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT02514551·245 enrolled

International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer

Approved for marketing· Eli Lilly logo

Eli Lilly··NCT02065765

Phase 2 Study of Novel SEQUEnced Immunotherapy (Pembrolizumab) With Anti-angiogenesis and Chemotherapy in Advanced Gastric and gastroesophageaL Junction (GEJ) Adenocarcinoma

Active, not recruiting·HHarry H Yoon·Phase 2·NCT04069273·58 enrolled

A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared With Investigator's Choice of Therapy in Second- or Later-Line Adult Participants With Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (CLARITY Gastric 01)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06346392·594 enrolled

Gastroesophageal Junction Adenocarcinoma6 trials

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03704077

A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT02539225·191 enrolled

MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Withdrawn·UUniversity of Southern California·Phase 1/2·NCT03739801

Show 3 more trials

Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis

Completed·SSamsung Medical Center·Phase 2·NCT02628951·62 enrolled

Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France

Approved for marketing· Eli Lilly logo

Eli Lilly··NCT02307812

A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Terminated· Roche logo

Roche·Preclinical·NCT03281369·219 enrolled

Gastroesophageal Junction Cancer6 trials

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

Recruiting·—·Phase 2·NCT04660760·116 enrolled

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06251973·37 enrolled

Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 3·NCT02934464·280 enrolled

Show 3 more trials

A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01983878·36 enrolled

Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients

Active, not recruiting·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT03760822·112 enrolled

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT03008278·51 enrolled

Lung Cancer5 trials

Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer

Terminated·GGenprex, Inc.·Phase 1/2·NCT05062980·5 enrolled

Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)

Withdrawn·SSWOG Cancer Research Network·Phase 2·NCT04267913

Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)

Unknown status·MMasahiro Tsuboi·Phase 2·NCT04040361·24 enrolled

Show 2 more trials

A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02789345·29 enrolled

A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02079636·142 enrolled

62 more indications

Gastric Adenocarcinoma5 trials

Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01253525·6 enrolled

Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction

Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·N/A·NCT04517747·20 enrolled

Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma

Completed·AArog Pharmaceuticals, Inc.·Phase 1·NCT03193918·30 enrolled

Show 2 more trials

A Phase 1/1b Study of ASP2138 as Monotherapy and in Combination With Pembrolizumab and mFOLFOX6 or Ramucirumab and Paclitaxel in Participants With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination With mFOLFIRINOX in Participants With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression

Recruiting· Astellas logo

Astellas·Phase 1·NCT05365581·398 enrolled

A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

Recruiting·TToray Industries, Inc·Phase 2·NCT06038578·146 enrolled

Esophageal Cancer5 trials

A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01246960·168 enrolled

Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer

Completed· Pfizer logo

Pfizer·Phase 2/3·NCT04499924·17 enrolled

A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT02898077·440 enrolled

Show 2 more trials

Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers

Unknown status·AAthenex, Inc.·Phase 1·NCT02970539·36 enrolled

Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT02317991·65 enrolled

Adenocarcinoma4 trials

Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma

Completed·WWashington University School of Medicine·Phase 2·NCT03141034·40 enrolled

A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)

Terminated· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT04675983·36 enrolled

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00917384·355 enrolled

Show 1 more trial

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Active, not recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT04704934·490 enrolled

Breast Cancer3 trials

A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01427933·141 enrolled

Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00703326·1,144 enrolled

A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01256567·7 enrolled

Esophageal Adenocarcinoma3 trials

PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression

Completed·UUniversity of Chicago·Phase 2·NCT02213289·80 enrolled

Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma

Unknown status·UUniversity of Kansas Medical Center·Phase 1/2·NCT03995017·34 enrolled

Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma

Unknown status·PP. C. Thuss-Patience·Phase 2·NCT03966118·59 enrolled

Advanced Cancer3 trials

A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer

Terminated· Eli Lilly logo

Eli Lilly·Phase 1·NCT04557384·3 enrolled

A Study of LY2801653 in Advanced Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01285037·190 enrolled

A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT02082210·97 enrolled

Hepatocellular Carcinoma3 trials

Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 1·NCT05856864·30 enrolled

A Study of LY2157299 in Participants With Hepatocellular Carcinoma

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01246986·204 enrolled

A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT02435433·399 enrolled

Pembrolizumab2 trials

Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)

Terminated· Sanofi logo

Sanofi·Phase 2·NCT04394624·31 enrolled

Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

Recruiting·—·Phase 2·NCT04332367·59 enrolled

Metastatic NSCLC2 trials

Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC

Active, not recruiting·FFox Chase Cancer Center·Phase 2·NCT03527108·36 enrolled

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT02411448·545 enrolled

Tics2 trials

Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male Volunteers

Completed· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT05800418·88 enrolled

A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01634555·29 enrolled

Solid Tumors2 trials

A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01515306·48 enrolled

A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01567163·22 enrolled

Liver Cancer2 trials

Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00627042·42 enrolled

A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02069041·8 enrolled

Colorectal Cancer2 trials

Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT01079780·136 enrolled

A Study of Ramucirumab or Icrucumab in Colorectal Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01111604·158 enrolled

Metastatic Colorectal Cancer2 trials

A Study in Second Line Metastatic Colorectal Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT01183780·1,072 enrolled

RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 3·NCT03520946·430 enrolled

Advanced Solid Tumors2 trials

A Study in Participants With Advanced Solid Tumors

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01682135·28 enrolled

A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors

Terminated· Eli Lilly logo

Eli Lilly·Phase 1·NCT02597036·62 enrolled

Immune2 trials

Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC

Withdrawn·WWashington University School of Medicine·Phase 2·NCT05007769

Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC

Completed·WWashington University School of Medicine·Phase 2·NCT03689855·21 enrolled

Gastroesophageal Adenocarcinoma2 trials

A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of Investigational Agents in Combination With Standard of Care Treatments as the Second-Line Treatment of Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06445972·210 enrolled

A Randomized Phase II Study of Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma

Recruiting·CCanadian Cancer Trials Group·Phase 2·NCT06043427·168 enrolled

Solid Tumor2 trials

A Phase 1 Study of ASP1002 in Participants With Metastatic or Locally Advanced Solid Tumors

Recruiting· Astellas logo

Astellas·Phase 1·NCT05719558·798 enrolled

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors

Active, not recruiting·TToray Industries, Inc·Phase 1·NCT03872947·138 enrolled

Advanced Refractory Solid Tumors1 trial

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02791334·164 enrolled

Carcinoid Tumor1 trial

A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

Completed·—·Phase 2·NCT02795858·43 enrolled

Fluorouracil1 trial

A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01286818·6 enrolled

Patients With Solid Tumors1 trial

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Terminated·EElevation Oncology·Phase 1·NCT05980416·88 enrolled

Ovarian Cancer1 trial

Study of Ramucirumab in Ovarian Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00721162·60 enrolled

Synovial Sarcoma1 trial

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma

Terminated· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT04145700·23 enrolled

Pancreatic Adenocarcinoma1 trial

RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Completed·HHellenic Cooperative Oncology Group·Phase 1/2·NCT03745430·54 enrolled

Refractory Solid Tumors1 trial

A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02564198·29 enrolled

Glioblastoma Multiforme1 trial

Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00895180·80 enrolled

Advanced NSCLC1 trial

Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy

Terminated·RROGER S KERESZTES MD·Phase 2·NCT03904108·3 enrolled

Advanced Cancers1 trial

A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02745769·23 enrolled

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT02426125·530 enrolled

Patients With Advanced Solid Tumors1 trial

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

Active, not recruiting·FFBD Biologics Limited·Phase 1/2·NCT06771622·500 enrolled

Transitional Cell Carcinoma1 trial

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02443324·175 enrolled

Peritoneal Metastases1 trial

Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases

Recruiting·—·Phase 1·NCT06675136·30 enrolled

Combination Therapy1 trial

A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02359058·18 enrolled

Nivolumab1 trial

A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer

Completed·NNational Cancer Center, Japan·Phase 1/2·NCT02999295·46 enrolled

Stomach Cancer1 trial

A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT02314117·645 enrolled

Renal Cancer1 trial

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Completed· Novartis logo

Novartis·Phase 1·NCT03798626·167 enrolled

GastroEsophageal Junction (GEJ) Cancer1 trial

A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT02443883·164 enrolled

Locally Advanced1 trial

Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

Completed·SSWOG Cancer Research Network·Phase 2·NCT03694002·21 enrolled

Biliary Cancer1 trial

Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02520141·61 enrolled

Pancreatic Cancer1 trial

Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer

Completed·—·Phase 2·NCT02581215·84 enrolled

Renal Cell Carcinoma1 trial

A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00515697·39 enrolled

PD-L1 Positive1 trial

Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma

Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT05980000·37 enrolled

Gastrointestinal1 trial

A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02572687·85 enrolled

Gemcitabine1 trial

A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM

Completed·GGruppo Oncologico Italiano di Ricerca Clinica·Phase 2·NCT03560973·164 enrolled

Mesothelioma1 trial

Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

Terminated·—·Phase 2·NCT03502746·34 enrolled

Non-Squamous Non-Small Cell Lung Cancer1 trial

A Phase 3 Open Label Randomized Study of Telisotuzumab Adizutecan Compared to Standard of Care in Subjects With Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer Expressing c-Met Protein Level Above a Defined Cutoff

Not yet recruiting· AbbVie logo

AbbVie·Phase 3·NCT07821684·660 enrolled

Metastatic Esophageal Adenocarcinoma1 trial

Phase I/II Study of Abemaciclib + Ramucirumab in Metastatic Esophageal/Gastroesophageal Junction Carcinomas

Completed·BBaylor Research Institute·Preclinical·NCT04921904·26 enrolled

Advanced Esophageal Adenocarcinoma1 trial

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients With PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)

Recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT06203600·224 enrolled

Metastatic Lung Non-Squamous Non-Small Cell Carcinoma1 trial

A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04310007·117 enrolled

HER2-Negative1 trial

A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate Denikitug as Monotherapy or in Combination With Nivolumab or Chemotherapy in Participants With HER2-Negative, Unresectable, Recurrent, and/or Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

Recruiting· Gilead logo

Gilead·Phase 2·NCT07546812·120 enrolled

Metastatic Small Intestinal Adenocarcinoma1 trial

Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma

Recruiting·SSWOG Cancer Research Network·Phase 2·NCT04205968·94 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

A Prospective Phase I and II Trial of Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Completed·WWashington University School of Medicine·Preclinical·NCT03650764·43 enrolled

Neoplasms1 trial

CAMPFIRE: Children's and Young Adult Master Protocol for Innovative Pediatric Research

Recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT05999994·105 enrolled

Desmoplastic Small Round Cell Tumor1 trial

A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor

Completed· Eli Lilly logo

Eli Lilly·Preclinical·NCT04145349·30 enrolled

Advanced or Metastatic Solid Tumor1 trial

Platform Study of AB122 Based Treatments in Patients With Advanced Solid Tumors

Recruiting· Taiho Pharmaceutical Co., Ltd. logo

Taiho Pharmaceutical Co., Ltd.·Phase 1·NCT04999761·917 enrolled

Lung1 trial

A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade

Active, not recruiting·EEmory University·Phase 2·NCT04340882·30 enrolled

Biliary Tract Cancer1 trial

Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT02711553·309 enrolled

Advanced or Metastatic Non-small Cell Lung Cancer1 trial

A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT06996782·152 enrolled

Advanced Gastric or EGJ Cancer1 trial

Ramucirumab Plus Irinotecan / Leucovorin / 5-FU Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed One Prior Line of Palliative Chemotherapy - The Phase II/III RAMIRIS Study

Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Preclinical·NCT03081143·429 enrolled

Regulatory

FDA Approval Timeline[4]

Apr 21, 2014

CYRAMZA

BLA BLA125477

Sources

References

[1]
ClinicalTrials.gov — 137 trial records for Ramucirumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ramucirumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ramucirumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA125477). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Vascular Endothelial Growth Factor Receptor 2 Inhibitor[2]
Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Eli Lilly

Cyramza

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Trials by Indication[1]

Non-Small Cell Lung Cancer18 trials

Gastric Cancer10 trials

Gastroesophageal Junction Adenocarcinoma6 trials

Gastroesophageal Junction Cancer6 trials

Lung Cancer5 trials

Gastric Adenocarcinoma5 trials

Esophageal Cancer5 trials

Adenocarcinoma4 trials

Breast Cancer3 trials

Esophageal Adenocarcinoma3 trials

Advanced Cancer3 trials

Hepatocellular Carcinoma3 trials

Pembrolizumab2 trials

Metastatic NSCLC2 trials

Tics2 trials

Solid Tumors2 trials

Liver Cancer2 trials

Colorectal Cancer2 trials

Metastatic Colorectal Cancer2 trials

Advanced Solid Tumors2 trials

Immune2 trials

Gastroesophageal Adenocarcinoma2 trials

Solid Tumor2 trials

Advanced Refractory Solid Tumors1 trial

Carcinoid Tumor1 trial

Fluorouracil1 trial

Patients With Solid Tumors1 trial

Ovarian Cancer1 trial

Synovial Sarcoma1 trial

Pancreatic Adenocarcinoma1 trial

Refractory Solid Tumors1 trial

Glioblastoma Multiforme1 trial

Advanced NSCLC1 trial

Advanced Cancers1 trial

Gastric1 trial

Paclitaxel1 trial

Urothelial Cancer1 trial

Patients With Advanced Solid Tumors1 trial

Transitional Cell Carcinoma1 trial

Peritoneal Metastases1 trial

Combination Therapy1 trial

Nivolumab1 trial

Stomach Cancer1 trial

Renal Cancer1 trial

GastroEsophageal Junction (GEJ) Cancer1 trial

Locally Advanced1 trial

Biliary Cancer1 trial

Pancreatic Cancer1 trial

Renal Cell Carcinoma1 trial

PD-L1 Positive1 trial

Gastrointestinal1 trial

Gemcitabine1 trial

Mesothelioma1 trial

Non-Squamous Non-Small Cell Lung Cancer1 trial

Metastatic Esophageal Adenocarcinoma1 trial

Advanced Esophageal Adenocarcinoma1 trial

Metastatic Lung Non-Squamous Non-Small Cell Carcinoma1 trial

HER2-Negative1 trial

Metastatic Small Intestinal Adenocarcinoma1 trial

Head and Neck Squamous Cell Carcinoma1 trial

Neoplasms1 trial

Desmoplastic Small Round Cell Tumor1 trial

Advanced or Metastatic Solid Tumor1 trial

Lung1 trial

Biliary Tract Cancer1 trial

Advanced or Metastatic Non-small Cell Lung Cancer1 trial

Advanced Gastric or EGJ Cancer1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News